免疫系统中,负向调控T淋巴细胞激活的因子称为免疫检查点分子,免疫检查点分子在限制机体免疫系统过度激活、维持机体免疫稳态过程中发挥重要作用。细胞毒性T淋巴细胞抗原4(Cytotoxic T lymphocyte antigen 4, CTLA4)和程序性细胞死亡1(Programmed cell death 1, PD...
(T细胞的活化)1987年,法国免疫学家Pierre Golstein(皮埃尔-戈尔斯坦)实验室在自然杂志上发文,他们在寻找CD8+杀伤型T细胞的“分子武器”时,从活化的CD8+T细胞中分离出一个cDNA,并称之为细胞毒性T淋巴细胞相关蛋白4(CTLA-4,Cytotoxic T lymphocyte-associated...
Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–9553. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271–275...
[1] Therapeutic use of anti-CTLA-4 antibodies. Int Immunol. 2015, 27(1):3-10. [2] Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti‒CTLA-4 antibodies. J Exp Med. 2009,3;206(8):1717-25....
Anti-CTLA-4 and anti-PD-1 checkpoint- blockade therapies target distinct tumor- infiltrating T cell populations to induce tumor rejection. 尽管PD-1和CTLA-4靶向治疗已经能够提高癌症患者的平均预期寿命,但仍有诸多局限性。虽然CTLA-4抗体和PD-1抗体的联合或顺序疗法正在火热展开,但对于疗效、用药的持久性和...
关键字: CTLA4;CD152; CD152 antigen;Celiac disease 3;CELIAC3;CTLA ;Cytotoxic T cell ass;CTLA4_HUMAN;公司简介 上海沪震实业有限公司是一家集研发、生产和销售于一体的生命科学实验室产品生物科技企业。主营产品:试剂盒,ELISA试剂盒,抗体,重组蛋白,血清,胎牛血清,细胞,原代细胞 细胞培养试剂,常用生化试剂。
cytotoxic T-lymphocyte protein 4 sCTLA4 soluble form transmembrane form 基因序列:NCBI_Gene:63835 蛋白序列: UniprotKB:A0A096MJE4 UniprotKB:G3V7D2 UniprotKB:Q62859 大鼠Rat Ctla4 靶点分子功能(预测) Predicted to enable signaling receptor activity. Involved in negative regulation of T cell proliferation ...
2. Vonderheide RH. CD4 T cell antitumor effector functions in the absence of B7-H1/PD-L1. Dallas, TX: American Association for Cancer Research; 2010:172. 3. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery. 2018;8(9):1069-1086...
CTLA4是一种共抑制分子,当CTLA4存在于CD4+和CD8+T淋巴细胞表面时可发挥作用,与抗原呈递细胞(Antigen-presenting cell,APC)上的配体CD80和CD86(B7-1和B7-2)的亲和力高于与T细胞上的共刺激受体CD28的亲和力。CTLA4及其配体CD80和CD86之间的相互作用抑制T细胞活性,从而促进肿瘤生长。
近日,来自比利时鲁汶大学的Diether Lambrechts 团队在Immunity 上发表题为CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy in head and neck squamous carcinoma的文章。通过对患者样本进行单细胞转录组分析,揭示了抗 PD-L1 加抗 CTLA4联合疗法增强了CD4...